Innate Pharma H1 2025 slides: strategic refocus on key assets extends cash runway
PositiveFinancial Markets

Innate Pharma has announced a strategic refocus on its key assets, which is expected to extend its cash runway into H1 2025. This move is significant as it highlights the company's commitment to optimizing its resources and prioritizing projects that could lead to breakthroughs in treatment. Investors and stakeholders will likely view this as a positive step towards ensuring the company's sustainability and growth in a competitive market.
— Curated by the World Pulse Now AI Editorial System